Prevention & lipidsGuideline or statement
2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement): A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
- Scientific statement
Recommendations
As issued by the authors
US cost-effectiveness threshold defined as $120 000 per quality-adjusted life year gained
New level of certainty framework summarizing the strength of the available evidence
Guidance for identifying and synthesizing relevant high-quality evidence, developing economic value statements, and communicating level of certainty in such statements
Special considerations related to CV drugs and devices; health equity considerations when interpreting cost-effectiveness analyses (CEAs); a reference case defined for future CEAs
Original publication
2025 AHA/ACC Statement on Cost/Value Methodology in Clinical Practice Guidelines (Update From 2014 Statement): A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published 25 September 2025. doi:10.1161/cir.0000000000001377
Summarised from the published abstract; every number is checked against it